Research Approach

Who

The LUNGevity Scientific Advisory Board meets annually to discuss research strategy and share new scientific developments. In addition, LUNGevity works with other lung cancer experts, who are recruited specifically to identify, among the grant applications that we receive, the most promising proposals for research into the early detection and treatment of lung cancer.

What

We are particularly interested in:

  1. Finding effective biomarkers that can be used to develop a non-invasive strategy for detecting early stage lung cancer.
  2. Developing more specific lung cancer imaging techniques by improving current software, hardware, data sharing methods and testing protocols.
  3. Creating more effective and efficient targeted therapies to treat lung cancer at all stages of the disease and helping to bring these drugs to patients quickly.

While we have particular interests, they do not bind us. LUNGevity welcomes innovative and novel approaches that can lead to the development of early detection and treatment practices of lung cancer.

How

LUNGevity issues three Requests for Application (RFAs) for translational lung cancer research per year, with the following areas of focus:

  • Early detection/diagnosis of lung cancer
  • Therapeutic agents/techniques that are effective post-diagnosis
  • Either topic in a career development context

The lung cancer experts who review the grant applications assess them on a number of measures, including the likelihood that the proposed research will exert a sustained, powerful influence on the research field involved.